Observations and analysis from the 37th Annual North American Spine Society (NASS) Meeting held October 12-14 in Chicago, IL.
SmartTRAK highlights the top news and themes at NASS 2022 affecting the markets for OrthoBio and Regenerative Medicine, including the Orthofix/SeaSpine merger, the ongoing controversy surrounding BMP-2, new product launches, company growth strategies and the latest research and innovation in intradiscal therapies.
Among the many topics covered in detail in this article are:
- A Spine Merger That Will Significantly Impact The Orthobiologics Landscape
- BMP-2 Safety Profile Remains an Open Issue
- Incremental Product Improvement Across OrthoBio Categories
- Spine Strategic Portfolio Strategies
- Intradiscal Treatments Take Center Stage
Undoubtedly, the proposed business combination of Orthofix and SeaSpine announced immediately prior to NASS was the most impactful news emanating from the meeting. On a proforma basis, the combined company is expected to generate approximately ...
To download and read the complete "OrthoBio-Focused Themes Emerging from NASS 2022" article by James Petricek, SmartTRAK's GM, OrthoBio and Regenerative Medicine, just click the button below.
SmartTRAK is a comprehensive, easy-to-use, business intelligence solution for the Life Sciences Industry that provides breaking updates on pertinent company news, potential treatments and guidance, international survey results, statistical analysis by country, studies, trial results, financial impact and more. All subscribers receive a Daily Updates email containing the latest need-to-know news curated by our expert analysts. It's the perfect way to start your day! If you would like to learn more about SmartTRAK, just click here.